Clinical-stage biotechnology developer Rezera Inc., formerly known as NodThera Inc., has set terms for its initial public offering to raise $200 million. The Boston-based company plans to market 16.67 million shares of common stock at $11.00 to $13.00 apiece, targeting a market capitalization near $249 million. For institutional healthcare allocators, the offering represents a key test of Wall Street appetite for Phase 3-ready inflammation therapeutics entering the autumn stock market window.

Headquartered in Boston, Massachusetts, Rezera operates a pre-revenue research and development model focused on oral small-molecule inhibitors targeting the NLRP3 inflammasome pathway. Led by Chief Executive Officer Geoff McDonough, the 21-person organization is advancing its lead candidate, ruvonoflast, into pivotal Phase 3 clinical trials for peripheral artery disease (PAD) alongside broader atherosclerotic cardiovascular indications. Prior to rebranding from NodThera in September 2026, the enterprise secured backing from institutional life-sciences venture sponsors including Novo Ventures, 5AM Ventures, F-Prime Capital, Sofinnova Partners, and Epidarex Capital, while pharmaceutical heavyweight GSK indicated interest in purchasing shares during the offering.

Under its amended Form S-1 registration statement, Rezera plans to list its common stock on the Nasdaq Global Market under the ticker symbol RZRA. The baseline offering comprises 16,666,667 shares priced between $11.00 and $13.00, delivering $200 million in gross proceeds at the $12.00 midpoint and upping its initial $100 million placeholder estimate. Jefferies, TD Cowen, Cantor, and Wedbush PacGrow are acting as joint bookrunning managers. Net proceeds are earmarked to fund Phase 3 clinical execution for ruvonoflast and extend the company’s operating cash runway from early 2027 into the first quarter of 2029.

Rezera’s market debut unfolds amidst renewed institutional investor interest in targeted anti-inflammatory therapies addressing residual cardiovascular risk. Peripheral artery disease affects millions of patients globally with limited oral disease-modifying options, presenting a substantial commercial opportunity if upstream NLRP3 inhibition demonstrates clinical superiority. Securing a liquid Nasdaq listing provides Rezera with dollar-denominated public capital to fund late-stage trials independently while enhancing strategic leverage for potential global commercial licensing partnerships.

Despite promising early tolerability across five completed human trials, Rezera remains a pre-revenue company carrying cumulative losses, including a $66.3 million net loss over the trailing twelve months ended June 30, 2026. The company faces standard binary regulatory risks from the U.S. Food and Drug Administration, where pivotal Phase 3 trial delays or safety signals could severely impair equity value. Furthermore, the competitive landscape in cardiovascular inflammation is intensifying, while reliance on single-asset execution exposes secondary trading to heightened biotech sector volatility.

The decisive question for institutional investors is whether Rezera’s market debut will sustain durable secondary support as a premier late-stage inflammation play, or trade with heightened volatility ahead of distant clinical readouts. Post-listing performance will hinge on timely Phase 3 patient enrollment, disciplined cash burn management, and potential strategic collaboration milestones with pharmaceutical partners. If ruvonoflast validates its clinical profile toward a projected 2029 regulatory submission, RZRA could command substantial multiple expansion; clinical setbacks, however, risk steep valuation compression.